Médicament Québec’s Impact Report – Advancing technological platforms in support of the ecosystem
January 7, 2026 – News from Médicament Québec
News
The VaxSynergy initiative — Unlocking Innovation in Vaccine Development through a Collaborative Ecosystem
October 23, 2025 – Funded activities
Establishing a platform to innovate therapeutic vaccines using immunomodulatory nanoparticles
October 21, 2025 – Funded activities
Médicament Québec Funds Two Additional Structuring Activities in Vaccine Technologies
October 14, 2025 – News from Médicament Québec
Lipid Nanoparticle Platform with Active Endosomal Escape System to enhance RNA internalization for RNA vaccines
September 23, 2025 – Funded activities
Preclinical tools and services to decode B- and T-cell repertoires induced by immune responses in non-human primates
September 18, 2025 – Funded activities
Development of a New CHO Platform for the Manufacturing of Intranasal Influenza Vaccines
September 16, 2025 – Funded activities
Creation of a Québec Human Immunology Network to Support the Provincial Vaccine Ecosystem
September 11, 2025 – Funded activities
Médicament Québec Funds Four Innovative Vaccine Technology Initiatives
September 9, 2025 – News from Médicament Québec
A platform led by Professor Jörg Fritz of McGill University to stimulate the discovery and development of RNA vaccines
June 26, 2025 – Funded activities
Optimization and Scale-Up of RNA Therapeutics Through Next-Generation Manufacturing
June 23, 2025 – Funded Activities
UdeM’s Biopharmaceutical Unit: playing a key role in drug development
In the media – June 8, 2021
Quebec gives UdeM $13 million to set up Médicament Québec
News from Médicament Québec – June 17 2021